BeOne Medicines AG (ONC) Stock: 36% Liver Cancer Response Rate Fuels Breakthrough Potential
TLDR BeOne’s liver cancer drug posts a 36% response rate in a Phase 1 clinical study. BGB-B2033 shows a 74.1%…
Market coverage 1 stories
TLDR BeOne’s liver cancer drug posts a 36% response rate in a Phase 1 clinical study. BGB-B2033 shows a 74.1%…